These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37429175)

  • 1. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surgical therapy of hepatic fibrolamellar carcinoma].
    Meriggi F; Forni E
    Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytologic features of fibrolamellar carcinoma with mucin production: a rare variant of combined hepatocellular-cholangiocarcinoma.
    Rosa M; Mohammadi A
    Diagn Cytopathol; 2014 May; 42(5):431-5. PubMed ID: 23008149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
    Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
    J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
    Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
    Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
    Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellularcholangiocarcinoma.
    Anysz-Grodzicka A; Podgorska J; Cieszanowski A
    Curr Med Imaging Rev; 2019; 15(3):269-280. PubMed ID: 31989878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
    Abdelhamed W; El-Kassas M
    World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrolamellar Carcinoma: What Is New and Why It Matters.
    Graham RP
    Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 15. Review of the clinicopathologic features of fibrolamellar carcinoma.
    Torbenson M
    Adv Anat Pathol; 2007 May; 14(3):217-23. PubMed ID: 17452818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.
    Mayo SC; Mavros MN; Nathan H; Cosgrove D; Herman JM; Kamel I; Anders RA; Pawlik TM
    J Am Coll Surg; 2014 Feb; 218(2):196-205. PubMed ID: 24315886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation.
    McLarney JK; Rucker PT; Bender GN; Goodman ZD; Kashitani N; Ros PR
    Radiographics; 1999; 19(2):453-71. PubMed ID: 10194790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrolamellar Carcinoma: A Concise Review.
    Lin CC; Yang HM
    Arch Pathol Lab Med; 2018 Sep; 142(9):1141-1145. PubMed ID: 30141990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.